Pfizer - PFE STOCK NEWS

Pfizer has launched 'An Accord for a Healthier World', aiming to provide patent-protected medicines and vaccines on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. This initiative includes partnerships with five initial countries: Rwanda, Ghana, Malawi, Senegal, and Uganda. Key objectives include improving healthcare infrastructure and access to essential medicines to reduce health inequities. Pfizer will offer 23 medicines and vaccines, with future products added to the Accord as they become available.

Pfizer announces the launch of ‘An Accord for a Healthier World’, providing its patented medicines and vaccines on a not-for-profit basis to 1.2 billion people across 45 lower-income countries. The initiative aims to address health inequities and includes collaboration with health officials from Rwanda, Ghana, Malawi, Senegal, and Uganda. Pfizer commits to making available 23 medicines and vaccines and streamlining regulatory pathways to improve access. The Accord emphasizes global health equity, with potential impacts on the lives of nearly one million annually in these regions.

Pfizer Inc. (NYSE: PFE) announced successful results from two pivotal studies of etrasimod for moderately-to-severely active ulcerative colitis (UC) at Digestive Disease Week 2022. Both Phase 3 trials, ELEVATE UC 52 and ELEVATE UC 12, met all primary and key secondary endpoints, showing significant improvement in clinical remission rates. In ELEVATE UC 52, 32.1% of patients on etrasimod achieved clinical remission at week 52 versus 6.7% for placebo. Safety profiles were consistent with previous studies. Regulatory filings are anticipated later this year.

Pfizer and BioNTech announced that their COVID-19 vaccine, with a third 3-µg dose for children under 5, met all immunobridging criteria for Emergency Use Authorization. A trial involving 1,678 children showed a favorable safety profile similar to placebo, with vaccine efficacy of 80.3% against symptomatic COVID-19 during the Omicron variant's surge. The companies plan to submit updated data to the FDA and other global regulators soon. The trial aims to provide strong protection against COVID-19 in young children, building on previous successful adult and adolescent studies.

The U.S. FDA has expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to include a booster dose for children aged 5 to 11. This booster, a 10-µg dose, can be administered at least five months after the second dose. Over 8 million children in this age group have completed the primary series. Data from clinical trials showed a strong immune response against both the Omicron variant and the wild-type virus, with no new safety issues reported.

Astellas Pharma will present 13 abstracts at the 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress, focusing on advanced and rare cancers, including prostate and pancreatic cancers. Highlights include findings from Phase 3 and 2 trials for therapies like enfortumab vedotin and zolbetuximab. Presentations aim to enhance treatment strategies for metastatic cancers. Astellas emphasizes its commitment to advancing oncology through innovative research and strategic collaborations, particularly with Pfizer on enzalutamide.

Pfizer has announced its acquisition of Biohaven, the maker of NURTEC® ODT, for approximately $11.6 billion. Shareholders will receive $148.50 per share in cash and shares in a new company retaining Biohaven's non-CGRP assets. The acquisition enhances Pfizer's Internal Medicine pipeline, focusing on migraine treatments with high market potential. NURTEC is already the leading migraine therapy in the U.S. The deal includes the purchase of Biohaven's CGRP programs and is expected to close by early 2023, pending approvals.

Pfizer (PFE) reported strong Q1 2022 revenues of $25.7 billion, marking an 82% operational growth. Excluding COVID-related revenues from Comirnaty and Paxlovid, operational growth was 2%. Reported diluted EPS was $1.37, with an adjusted EPS of $1.62. Despite challenges from foreign exchange impacts, Pfizer reaffirms its full-year revenue guidance of $98-102 billion and adjusted EPS of $6.25-6.45. The company has also begun share repurchases, totaling $2 billion in Q1. Key developments include continued success in vaccine distribution and ongoing clinical trials.

MOBItalks returns to New York on May 14, 2022, focusing on alternative wellness and community empowerment for Black gay men. Presented by ViiV Healthcare and the Mobilizing Our Brothers Initiative (MOBI), the event features speakers and provides networking opportunities. Attendees can enjoy free professional headshots and brunch by Cornbread26 Food Co. MOBI, active since 2017, aims to enhance personal development and community wellness, having contributed over $1 million to the Black queer community. For registration, visit mobi-nyc.com/nyctalks.